5736 related articles for article (PubMed ID: 2318137)
1. [The mechanisms of a decrease in the toxic action of cisplatin when administered jointly with preparation K-2-9 to mice with melanoma B16].
Chekhun VF; Pel'kis FP; Serebriakova EA; Singin AS; Sokolova IS; Negreĭ GZ; Kulik GI
Eksp Onkol; 1990; 12(2):68-71. PubMed ID: 2318137
[TBL] [Abstract][Full Text] [Related]
2. [Modification of the toxic effects of cis-dichlorodiammineplatinum].
Kulik GI; Chekhun VF; Pel'kis FP; Korol' VI; Boĭm TM
Eksp Onkol; 1985; 7(6):55-8. PubMed ID: 4085400
[TBL] [Abstract][Full Text] [Related]
3. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.
Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Zuhowski EG; Pluim D; Joseph E; Hamburger DR; Working PK; Colbern G; Tonda ME; Potter DM; Eiseman JL
Cancer Chemother Pharmacol; 2004 Apr; 53(4):329-36. PubMed ID: 14673619
[TBL] [Abstract][Full Text] [Related]
4. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin.
Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Hamburger DR; Delauter BJ; Grim A; Zuhowski EG; Joseph E; Pluim D; Potter DM; Eiseman JL
Clin Cancer Res; 2002 Sep; 8(9):2992-9. PubMed ID: 12231546
[TBL] [Abstract][Full Text] [Related]
5. Influence of a novel platinum compound--cis-dichloro (dimethylsulphoxide) (1-beta-D-rybofuranosyl-1,2,4-triazolo-3-arboxyamide) platinum (II)--"Pt-rib-1"--on cell cycle and apoptosis in ClS91 and B16 mouse melanoma in vitro.
Drewa T; Olszewska-Słonina D; Woźniak A; Styczyński J; Drewa G; Szłyk E; Lakomska I; Kobe J; Czajkowski R
Acta Pol Pharm; 2004; 61(1):39-44. PubMed ID: 15259856
[TBL] [Abstract][Full Text] [Related]
6. Antitumor, nephrotoxic and clastogenic effect of cis-DDP with DDTC or NAC.
Konstantinov S; Topashka-Ancheva M; Karaivanova M; Zoneva G; Galova I
Neoplasma; 1994; 41(5):253-8. PubMed ID: 7854494
[TBL] [Abstract][Full Text] [Related]
7. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors.
Dominguez MF; Macias RI; Izco-Basurko I; de La Fuente A; Pascual MJ; Criado JM; Monte MJ; Yajeya J; Marin JJ
J Pharmacol Exp Ther; 2001 Jun; 297(3):1106-12. PubMed ID: 11356935
[TBL] [Abstract][Full Text] [Related]
8. Influence of melanoma B16 on the pharmacokinetics of mitoguazone in mice.
Amlacher R; Baumgart J; Mackowiak A; Sühnel J; Horn U; Bubner M; Hoffmann H
Pharmazie; 1991 Jan; 46(1):44-6. PubMed ID: 1857730
[TBL] [Abstract][Full Text] [Related]
9. Distribution of cisplatin in tumor-free versus tumor-bearing B6D2F1 mice.
Amlacher R; Böckel V; Mackowiak A; Stadeler M; Frankenberg D; Hoffmann H
Arch Geschwulstforsch; 1990; 60(5):341-7. PubMed ID: 2241510
[TBL] [Abstract][Full Text] [Related]
10. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
Rice JR; Gerberich JL; Nowotnik DP; Howell SB
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2248-54. PubMed ID: 16609041
[TBL] [Abstract][Full Text] [Related]
11. [The role of the mono-oxygenase system in realizing the biological effects of cisplatin].
Chekhun VF; Pel'kis FP; Kulik GI
Vopr Onkol; 1991; 37(9-10):954-8. PubMed ID: 1842656
[TBL] [Abstract][Full Text] [Related]
12. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate.
Bodenner DL; Dedon PC; Keng PC; Katz JC; Borch RF
Cancer Res; 1986 Jun; 46(6):2751-5. PubMed ID: 3009000
[TBL] [Abstract][Full Text] [Related]
13. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
14. [Experimental modification of the nephro- and gastroenterotoxicity of cisplatin].
Kulik GI; Chekhun VF; Pel'kis FP; Boĭm TM
Vopr Onkol; 1988; 34(12):1477-81. PubMed ID: 3218150
[TBL] [Abstract][Full Text] [Related]
15. Cis-diamminedichloroplatinum (II)-procaine pharmacokinetic interaction in mice bearing P388 leukemia.
Esposito M; Vannozzi MO; Viale M; Pellecchia C; Merlo F; Cadoni A; Cafaggi S; Parodi B; Lerza R; Poirier MC
Anticancer Res; 1993; 13(5A):1511-6. PubMed ID: 8239529
[TBL] [Abstract][Full Text] [Related]
16. [The effect of antitumor preparations on the energy metabolism of melanoma B16 in mice. A 31P-NMR method in vivo].
Shkarin PIu; Sokolova IS; Gorbacheva LB; Sibel'dina LA
Dokl Akad Nauk SSSR; 1989; 309(4):996-9. PubMed ID: 2635671
[No Abstract] [Full Text] [Related]
17. Treatment and prophylaxis of experimental liver metastases of M5076 reticulosarcoma with cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) encapsulated in multilamellar vesicles.
Perez-Soler R; Khokhar AR; Lopez-Berestein G
Cancer Res; 1987 Dec; 47(24 Pt 1):6462-6. PubMed ID: 3315188
[TBL] [Abstract][Full Text] [Related]
18. [The action of amino acid di[2-haloethyl]hydrazides on DNA synthesis in normal and tumor cells and on the cell cycle kinetics in mice with melanoma B-16].
Gorneva GA; Bergol'ts VV; Mladenova IP; Smirnova ZS; Nikolaeva TG
Eksp Onkol; 1989; 11(1):63-5. PubMed ID: 2494034
[TBL] [Abstract][Full Text] [Related]
19. [Combined effect of PT-050 (recombinant human TNF) and antitumor drugs on syngeneic murine tumors].
Nakata K; Yoshida H; Kashimoto S; Sohmura Y; Nakamura S; Taguchi T
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3186-93. PubMed ID: 3096217
[TBL] [Abstract][Full Text] [Related]
20. [Mechanisms of the antitumor action of spirobromine in mice with leukemia P-388].
Sokolova IS; Riabokon' NA; Chernov VA; Gorbacheva LB
Izv Akad Nauk SSSR Biol; 1989; (5):660-5. PubMed ID: 2584530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
